Please assess the completion status of the following clinical trial:

Trial Title: Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, aged 18 years or older~2. ARV multi-experienced patients (i.e. experienced at least two prior regimens) with need to change current ARV therapy, including:~   * HIV-1 infected patients with documented therapeutic failure,~  * HIV-2 infected patients with documented therapeutic failure~  * HIV infected patients in virologic suppression who needed to change ARV due to inacceptable toxicity, as determined by the investigator, including patients who needed to replace T20~3. Raltegravir-naïve patients who initiated raltegravir since the EAP Program, with optimized background therapy(OBT)~4. Patient who has been followed at the same clinical site since the start of raltegravir~Exclusion Criteria:~1. Acute or decompensated chronic hepatitis. Patients with serum aminotransferase levels 10 times the upper limit of the normal range or higher (grade 4)~2. Patients who presented resistance to drugs included in OBT (namely, etravirine, darunavir or maraviroc)~3. Non-existing medical records for viral load and TCD4 at baseline, week 24 and 48

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CohortHIV (Type: None): Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.

Based on this trial design, predict the completion outcome and termination type (if applicable).